US
US Contraceptive Innovations Market Industry Trends and Forecast to 2034: Segmented by (Product, Hormone, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $1.88 Bn.
Canada at 5.9% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$774.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.81 Bn | — | — |
| 2025 (base) | $1.88 Bn | +$70.7 Mn | — |
| 2026 (forecast) | $1.96 Bn | +$73.5 Mn | +3.9% |
| 2027 (forecast) | $2.03 Bn | +$76.3 Mn | +8% |
| 2028 (forecast) | $2.11 Bn | +$79.3 Mn | +12.2% |
| 2029 (forecast) | $2.20 Bn | +$82.4 Mn | +16.5% |
| 2030 (forecast) | $2.28 Bn | +$85.6 Mn | +21.1% |
| 2031 (forecast) | $2.37 Bn | +$89.0 Mn | +25.8% |
| 2032 (forecast) | $2.46 Bn | +$92.4 Mn | +30.7% |
| 2033 (forecast) | $2.56 Bn | +$96.0 Mn | +35.8% |
| 2034 (forecast) | $2.66 Bn | +$99.8 Mn | +41.1% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$1.88 Bn
Canada
$384.9 Mn
China
$350.4 Mn
Japan
$262.9 Mn
Germany
$149.5 Mn
France
$122.6 Mn
UK
$109.2 Mn
Brazil
$105.8 Mn
Italy
$100.1 Mn
Ecuador
$101.1 Mn
Spain
$84.7 Mn
India
$86.5 Mn
Saudi Arabia
$74.9 Mn
Mexico
$72.6 Mn
Australia
$66.1 Mn
New Zealand
$46.7 Mn
Russia
$45.8 Mn
South Africa
$31.0 Mn
UAE
$27.3 Mn
Egypt
$15.4 Mn
Philippines
$9.8 Mn
Malaysia
$8.4 Mn
Hong Kong
$7.0 Mn
Thailand
$6.4 Mn
Singapore
$6.3 Mn
Kenya
$3.1 Mn
Contraceptive innovations are newer birth-control options such as hormone-free gels, long-acting injectables, vaginal rings and over-the-counter pills.
Key segments of the contraceptive Innovations market include product (Over-the-Counter Pills, Long-Acting Injectables and Vaginal Rings) and hormone (Hormonal and Non-Hormonal).
Greater awareness of women's health needs, more funding for female-focused research, later pregnancies and an ageing female population are driving the contraceptive Innovations market. New products designed around women's biology and digital care are improving access.
Femtech, personalised care and new treatments for under-served conditions open strong growth for the contraceptive Innovations market, especially as employers and payers add women's health benefits.
Under-diagnosis, stigma around some conditions, limited insurance coverage and a long history of under-research in women's health hold back the contraceptive Innovations market.
The contraceptive Innovations market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for contraceptive Innovations. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Contraceptive Innovations right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
US · 1 shared keyword
US · 1 shared keyword
US
US
US
US
Healthcare Services · US
Medical Devices · US
Healthcare Services · US
Digital Health · US
Healthcare Services · US
Healthcare Services · US
